Skip to main content
. 2022 Jan 3;2(1):15–24. doi: 10.21873/cdp.10071

Table I. Patient characteristics.

graphic file with name cdp-2-16-i0001.jpg

Group A: Patients who experienced ≥30% increase in SV at time ii (immediately after completing oxaliplatin-based chemotherapy) compared with time i (immediately before oxaliplatin-based chemotherapy). Group B: patients who did not experience ≥30% increase in SV at time ii compared with time i. BMI: Body mass index; tub 1: well differentiated tubular adenocarcinoma; tub 2: moderately differentiated adenocarcinoma; pap: papillary adenocarcinoma; muc: mucinous adenocarcinoma.